Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Capital Expenditures of $121000.0 for Q4 2025, down 97.67% year-over-year from $5.2 million in Q4 2024, and up 436.11% quarter-over-quarter from -$36000.0 in Q3 2025.
Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $121000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 97.67% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at -$108000.0 (down 103.43% YoY), while the FY2024 annual figure was $3.2 million, down 43.75% from the prior year.
- Capital Expenditures for Q4 2025 stood at $121000.0, up from -$36000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $8.6 million in Q1 2023, with the low at -$7.7 million in Q2 2023.
- The 5-year median for Capital Expenditures is $256000.0 (2022), against an average of $672000.0.
- Peak annual rise in Capital Expenditures reached 2107.93% in 2023, while the deepest fall reached 1895.88% in 2023.
- Entrada Therapeutics' Capital Expenditures stood at $2.7 million in 2021, then plunged by 178.7% to -$2.1 million in 2022, then jumped by 146.68% to $976000.0 in 2023, then soared by 432.99% to $5.2 million in 2024, then sank by 97.67% to $121000.0 in 2025.
- Business Quant data shows TRDA's Capital Expenditures at $121000.0 in Q4 2025, -$36000.0 in Q3 2025, and -$193000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Jun 30, 2025 | -193,000.00 |
| Jun 30, 2025 | -193,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Mar 31, 2025 | 108,000.00 |
| Dec 31, 2024 | 5.20 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |